Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

Inclusion Criteria: * After the physician decision has been made to use biphasic insulin aspart 30 or insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before.Particular attention should be paid to the drug interactions that are listed within the product label Exclusion Criteria: * Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit * Subjects currently being treated with biphasic insulin aspart 30 or insulin detemir * Subjects who were previously enrolled in this study * Subjects with a hypersensitivity to biphasic insulin aspart 30 or insulin detemir or to any of the excipients * Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months